Tandem Diabetes Care (TNDM) Cash & Equivalents Growth (1y) (2014 - 2026)
Tandem Diabetes Care (TNDM) Cash & Equivalents Growth (1y) (2014 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 198.70 Bn | 193.10 Bn | 7.27 Bn | -26.57% |
| 2 | Stryker | 125.85 Bn | 122.37 Bn | 4.50 Bn | 42.78% |
| 3 | Medtronic | 118.44 Bn | 109.22 Bn | 6.41 Bn | -12.13% |
| 4 | Boston Scientific | 72.64 Bn | 72.10 Bn | 3.85 Bn | 0.94% |
| 5 | Edwards Lifesciences | 51.94 Bn | 47.69 Bn | 1.35 Bn | -11.19% |
| 6 | Dexcom | 34.48 Bn | 32.53 Bn | 830.00 Mn | -4.66% |
| 7 | GE HealthCare Technologies | 33.60 Bn | 31.49 Bn | 2.18 Bn | -44.03% |
| 8 | Koninklijke Philips | 26.30 Bn | 22.98 Bn | 4.55 Bn | 19.49% |
| 9 | Steris | 23.00 Bn | 22.52 Bn | 684.20 Mn | 72.43% |
| 10 | Tandem Diabetes Care | 1.56 Bn | 1.10 Bn | 144.78 Mn | -2.02% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -2.02% |
| Mar 31, 2026 | 234.72% |
| Dec 31, 2025 | 30.91% |
| Sep 30, 2025 | 87.50% |
| Jun 30, 2025 | 34.42% |
| Mar 31, 2025 | -9.16% |
| Dec 31, 2024 | 17.61% |
| Sep 30, 2024 | -38.40% |
| Jun 30, 2024 | -63.52% |
| Mar 31, 2024 | -53.84% |
| Dec 31, 2023 | -65.88% |
| Sep 30, 2023 | -35.69% |
| Jun 30, 2023 | 13.73% |
| Mar 31, 2023 | 36.38% |
| Dec 31, 2022 | 142.36% |
| Sep 30, 2022 | 10.15% |
| Jun 30, 2022 | 16.62% |
| Mar 31, 2022 | -22.44% |
| Dec 31, 2021 | -24.77% |
| Sep 30, 2021 | -13.21% |